Dupixent Lawsuits
Dupixent was supposed to treat serious inflammatory conditions. It was not supposed to leave patients facing a cancer diagnosis.
Ankin Law is currently investigating Dupixent cancer claims involving cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. Dupixent lawsuits allege that drugmakers Regeneron Pharmaceuticals and Sanofi Genzyme failed to properly warn patients and doctors about the risk.
If you or a loved one used Dupixent for more than 30 days and were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome, you may be eligible to file a Dupixent lawsuit.
Drug companies do not get to stay quiet about serious risks and leave patients to deal with the consequences. If Dupixent played a role in your cancer diagnosis, you deserve answers.
Call Ankin Law now to discuss your case. (312) 600-0000.
“Patients have a right to know the risks before they take a medication. If a drug company knew or should have known about a serious cancer risk and failed to warn people, they need to answer for that.”
— Attorney Howard Ankin
Table of Contents
We’ve Recovered Hundreds of Millions for Our Clients
Ankin Law has the resources, experience, and legal firepower to take on powerful companies when people are harmed. Our case results show what can happen when we make the other side answer for the damage they caused.
Why Are People Filing Dupixent Lawsuits?
People are filing Dupixent lawsuits because they allege the drug may be linked to cutaneous T-cell lymphoma, or CTCL, a rare form of non-Hodgkin lymphoma that affects the skin. Lawsuits claim that Sanofi and Regeneron failed to properly warn patients and doctors about the cancer risk.
Patients make medical decisions based on the information they are given. Doctors prescribe medications based on the risks they know about. If a drug company knows, or should know, that a medication may be linked to a serious condition like cancer, that risk needs to be clearly disclosed.
Dupixent lawsuits are not just about the diagnosis. They are about whether patients like you were given the full truth before taking the drug.
Many people who took Dupixent were already dealing with serious inflammatory conditions, including eczema, asthma, and other immune-related disorders. They trusted the medication to help them manage those conditions. Now they face questions about lymphoma, cancer treatment, and whether their diagnosis could have been avoided.
What Is Cutaneous T-Cell Lymphoma?
Cutaneous T-cell lymphoma, or CTCL, is a rare type of non-Hodgkin lymphoma that affects the skin. It happens when certain white blood cells, called T cells, become cancerous and build up in the skin.
CTCL can be difficult to diagnose because it may look like other skin conditions, including eczema, psoriasis, rashes, or dermatitis. That matters in Dupixent cases because some patients were prescribed Dupixent for inflammatory skin conditions before later being diagnosed with CTCL.
The two types of CTCL most often connected to Dupixent lawsuit investigations are mycosis fungoides and Sézary syndrome.
Mycosis fungoides is the most common form of CTCL. It may cause patches, plaques, tumors, itching, scaling, and skin lesions that can worsen over time.
Sézary syndrome is a more aggressive form of CTCL. It can affect the skin, blood, and lymph nodes, and may cause widespread redness, severe itching, swollen lymph nodes, and other serious complications.
Do You Qualify for a Dupixent Lawsuit?
You may qualify for a Dupixent lawsuit if you used Dupixent for one month or more and were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome.
Ankin Law is currently reviewing claims involving people who:
- Used Dupixent for more than 30 days
- Were diagnosed with CTCL, mycosis fungoides, or Sézary syndrome after using Dupixent
- Did not have a prior diagnosis of CTCL, mycosis fungoides, Sézary syndrome, leukemia, or another lymphoma before starting Dupixent
- Have medical records showing Dupixent use and the later cancer diagnosis
If you are not sure whether your diagnosis qualifies, call us anyway. We can review your situation and help you understand your legal options for free.
Chicago personal injury and workers’ compensation attorney Howard Ankin has a passion for justice and a relentless commitment to defending injured victims throughout the Chicagoland area. With decades of experience achieving justice on behalf of the people of Chicago, Howard has earned a reputation as a proven leader in and out of the courtroom. Respected by peers and clients alike, Howard’s multifaceted approach to the law and empathetic nature have secured him a spot as an influential figure in the Illinois legal system.
Illinois Registration Status: Active
What Evidence Can Help Support a Dupixent Lawsuit?
Dupixent lawsuits depend heavily on medical records, prescription history, diagnosis timing, and the details of your cancer treatment. The more clearly your records show when you used Dupixent and when symptoms or a CTCL diagnosis appeared, the stronger the case review may be.
Evidence that may help support a Dupixent lawsuit includes:
- Prescription records showing when you started and stopped using Dupixent
- Pharmacy records or injection records
- Medical records showing why Dupixent was prescribed
- Dermatology records, biopsy reports, pathology reports, or oncology records
- A diagnosis of CTCL, mycosis fungoides, or Sézary syndrome
- Records showing symptoms that developed or worsened after Dupixent use
- Photos of skin changes, lesions, rashes, plaques, or tumors
- Records of cancer treatment, specialist visits, medication changes, or ongoing monitoring
You do not need to have every record before calling Ankin Law. We’ll help you obtain the records and information needed to evaluate your claim.
Call (312) 600-0000 now.
What Do Dupixent Lawsuits Allege?
Dupixent lawsuits allege that Sanofi and Regeneron failed to properly warn patients and doctors about the potential risk of cutaneous T-cell lymphoma. Plaintiffs claim the companies knew, or should have known, that Dupixent may be linked to CTCL, but did not provide adequate warnings.
These lawsuits may involve claims that the drugmakers:
- Failed to properly warn about the potential risk of CTCL
- Failed to provide doctors with enough information about the cancer risk
- Minimized or failed to disclose safety concerns
- Failed to update warnings as more information became available
- Put patients at risk by not giving them the full picture before treatment
The issue is not just whether Dupixent helped treat eczema, asthma, or another inflammatory condition. The issue is whether patients and doctors were given the information they needed to make an informed decision.
When a drug company knows about a serious risk, it has a responsibility to say so clearly. If that did not happen, the company should be held accountable.
Current Status of Dupixent Lawsuits
Dupixent lawsuits are still in the early stages. According to current reports, there have not been any Dupixent settlements or jury verdicts yet.
In June 2026, Dupixent lawsuits were consolidated into multidistrict litigation, also known as an MDL. An MDL is not the same thing as a class action. In a class action, many people are grouped together in one lawsuit. In an MDL, individual lawsuits are transferred to one federal court, so similar claims can move through the legal process more efficiently.
That means your case may still be treated as your own case. Your medical history, Dupixent use, CTCL diagnosis, treatment, losses, and long-term prognosis all matter.
MDLs are often used when many people file similar lawsuits against the same companies. They can help streamline discovery, reduce repeated legal work, and allow key issues to be handled before one judge. Over time, some cases may be selected for bellwether trials. Those early trials can help both sides understand how juries may view the evidence.
Waiting can hurt your claim. Medical records can become harder to collect. Witnesses may become harder to reach. Legal deadlines can pass. If Dupixent may be connected to your CTCL diagnosis, now is the time to have your case reviewed.
How Ankin Law Can Help With a Dupixent Cancer Claim
Ankin Law is investigating claims involving Dupixent and cutaneous T-cell lymphoma. If you believe Dupixent may be connected to your diagnosis, we can review your case for free, explain what information may be important, and help determine whether you may have a claim.
Our job is to look at the timeline. When did you start using Dupixent? When did your symptoms change? When were you diagnosed with CTCL, mycosis fungoides, or Sézary syndrome? What do the medical records show?
If we move forward together, our team will gather records, investigate the facts, and build the strongest case possible. Depending on the circumstances, compensation may be available for medical expenses, lost wages, pain and suffering, ongoing treatment costs, and other losses related to your diagnosis.
A Dupixent lawsuit is not just about a medication. It is about what happened after you trusted that medication.
At Ankin Law, we believe people deserve straight answers. If we think you have a case, we will tell you. If we do not, we will tell you that too.
Frequently Asked Questions About Dupixent Lawsuits
Is There a Dupixent Class Action Lawsuit?
Dupixent lawsuits have been consolidated into multidistrict litigation, or an MDL. An MDL is different from a class action. In an MDL, individual lawsuits involving similar claims are handled together in one federal court for efficiency.
Your claim may still be evaluated based on your own Dupixent use, diagnosis, medical history, treatment, and losses.
Have There Been Any Dupixent Settlements?
There have not been any reported Dupixent settlements or jury verdicts yet. The litigation is still in the early stages.
That does not mean you should wait. Legal deadlines can apply, and medical records, prescription history, and diagnosis records may be important to your claim. If you believe Dupixent may be connected to your CTCL diagnosis, it is better to have your case reviewed now.
What Types of Cancer Are Connected to Dupixent Lawsuits?
Dupixent lawsuits focus on cutaneous T-cell lymphoma, or CTCL. The related diagnoses most often discussed in these cases include mycosis fungoides and Sézary syndrome.
CTCL is a rare type of non-Hodgkin lymphoma that affects the skin. It can be difficult to diagnose because symptoms may look like eczema, psoriasis, dermatitis, or other inflammatory skin conditions.
How Much Is a Dupixent Lawsuit Worth?
The value of your Dupixent lawsuit depends on your diagnosis, treatment, medical expenses, lost income, pain and suffering, long-term prognosis, and how the condition has affected your life.
No attorney can promise a specific settlement amount. Ankin Law can review your records, look at your losses, and explain what compensation may be available under the law.